The Life Sciences team advised Moderna, Inc. (Nasdaq: MRNA) on its underwritten public offering of 26,315,790 shares of common stock at a public offering price of $19.00 per share, before underwriting discounts and commissions. In addition, Moderna granted the underwriters a 30-day option to purchase up to an additional 3,947,368 shares of common stock at the public offering price, less underwriting discounts and commissions. Gross proceeds from the offering were approximately $500 million. Goodwin also advised Moderna on its initial public offering, the largest-ever U.S. biotech IPO, in 2018.
Moderna is a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients.
For additional details on the offering, please read the press release.